Cell, Therapy

NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

DelveInsight Business Research, LLP United States of America United Kingdom

 
+14699457679 
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/nk-cell-therapy-clinical-trial-pipeline-appears-robust-with-140-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302300920.html

en | boerse | 67925749 |